NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHORIC ACID-DEPENDANT STEROID DEHYDROGENASE INHIBITOR DERIVED FROM HUMAN BODY AND ANTICANCER AGENT OR PHARMACEUTICAL COMPOSITION FOR TREATING HYPERLIPIDEMIA CONTAINING SAME AS ACTIVE COMPONENT
서울대학교산학협력단;국립암센터;한국화학연구원;서울대학교산학협력단;국립암센터;한국화학연구원;SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION;NATIONAL CANCER CENTER;KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
发明人:
LEE BONG JIN,이봉진,LEE KYU YEON,이규연,LEE SANG JAE,이상재,KIM DONG GYUN,김동균,LEE JOO YOUN,이주연,JEONG KWAN YOUNG,정관령,YANG HEUI CHERL,양희철,LEE HYEON KYU,이현규,KIM HYOUN SOOK,김현숙
申请号：
KR1020190105425
公开号：
KR1020200026104A
申请日:
2019.08.27
申请国别(地区):
KR
年份:
2020
代理人:
摘要：
A nicotinamide adenine dinucleotide phosphoric acid-dependent steroid dehydrogenase (NSDHL) inhibitor provided in an aspect of the present invention can be used as an anticancer agent that can overcome resistance of an EGFR targeted anticancer agent, and also has an effect that can be used for treating hyperlipidemia.COPYRIGHT KIPO 2020본 발명의 일 측면에서 제공되는 니코틴아마이드 아데닌 다이뉴클레오타이드 인산 의존 스테로이드 탈수소효소(NSDHL) 저해제는, EGFR 타겟 항암제의 내성을 극복할 수 있는 항암제로 사용 가능할 뿐만 아니라 고지혈증 치료에도 사용 가능한 효과가 있다.
